Insider · CIK 0001348587
Patricia L Allen
director
Files at ZBIO (Zenas BioPharma, Inc.). First filing Feb 13, 2026, latest Feb 13, 2026.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
1 / 0
$500k bought, $0 sold
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
ZBIO: Zenas BioPharma, Inc.
ZBIOOct 9, 2026 · close 27.26
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 64Notable | Zenas BioPharma, Inc. | $500k 19,860 shares | - | +306% from low-40% from high |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 15, 2026 | ZBIO Zenas BioPharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 17, 2026 |
| Feb 12, 2026 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +5,000 | $23.77 | $119k | 5,000 | Feb 13, 2026 |
| Feb 12, 2026 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +5,700 | $24.34 | $139k | 10,700 | Feb 13, 2026 |
| Feb 12, 2026 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +5,000 | $26.50 | $133k | 15,700 | Feb 13, 2026 |
| Feb 13, 2026 | ZBIO Zenas BioPharma, Inc. | POpen-market purchase Common Stock | +4,160 | $26.36 | $110k | 19,860 | Feb 13, 2026 |
| Jun 10, 2025 | ZBIO Zenas BioPharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +18,500 | $0.00 | $0 | 18,500 | Jun 12, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.